1. Disease Overview

Patent ductus arteriosus (PDA) is a congenital heart defect in which the ductus arteriosus—a normal fetal blood vessel connecting the pulmonary artery to the aorta—fails to close after birth. In the womb this vessel lets blood bypass the not-yet-working lungs, and it normally closes within the first few days of life. When it stays open (patent), oxygen-rich blood from the higher-pressure aorta flows back into the pulmonary artery, increasing blood flow to the lungs and adding work for the heart.

PDA is one of the most common congenital heart defects, especially in premature infants, though it also occurs in full-term babies and can rarely persist into adulthood. It ranges from a tiny, silent defect to a large one causing heart failure and pulmonary hypertension. With timely closure—by medication, catheter device, or surgery—the outlook is excellent, and most children live normal, healthy lives.

2. Key Facts at a Glance

Aspect	Details
Also known as	Persistent ductus arteriosus, PDA, ductal patency
Body system affected	Cardiovascular system (heart, lungs, blood vessels)
Common in	Premature infants (especially <28 weeks), some full-term infants, rarely adults
Severity range	Tiny asymptomatic PDA to large PDA causing heart failure and pulmonary hypertension
Key treatments	NSAIDs (indomethacin, ibuprofen) in preterm infants; catheter device closure; surgical ligation
Outlook	Excellent with timely closure; most infants live normal, healthy lives

3. Alternative Names and Medical Terminology

Patent ductus arteriosus (PDA) — most common term
Persistent ductus arteriosus — emphasizes failure to close
Ductal patency — technical term for an open ductus
Hemodynamically significant PDA — large enough to affect heart function
Silent PDA — small PDA with no symptoms or murmur
PDA with Eisenmenger syndrome — reversed shunt from severe pulmonary hypertension (rare)

4. Relevant Heart, Lung or Vascular Anatomy

The ductus arteriosus connects the pulmonary artery to the aorta, lying near the aortic arch. In the fetus it shunts blood away from the fluid-filled, non-functional lungs. At birth, the lungs expand and pulmonary resistance falls, while rising blood oxygen makes the ductal muscle contract; the vessel normally closes within 1–2 weeks, leaving a fibrous remnant called the ligamentum arteriosum. In PDA the connection persists, and because aortic pressure now exceeds pulmonary pressure, blood flows left-to-right (aorta to pulmonary artery). The ductus may be tiny and insignificant or a large vessel causing major shunting.

5. How the Disease Affects the Body

In PDA, oxygen-rich blood flows backward from the aorta into the pulmonary artery, creating pulmonary overcirculation while the left atrium and left ventricle handle the extra returning volume. Some blood meant for the body simply recirculates through the lungs, reducing efficient systemic output.

Over time the effects progress: the left heart chambers enlarge, the pulmonary artery dilates, and the lungs become congested, making breathing harder. Infants tire during feeds and fail to gain weight. If untreated, a significant shunt leads to heart failure, and the lung arteries thicken so that pulmonary hypertension develops. In long-standing cases, pressures can rise so high that the shunt reverses (right-to-left)—Eisenmenger syndrome—causing low oxygen and cyanosis. The size of the ductus and how long it stays open largely determine how severe these effects become.

6. Types and Classification

By size: small (<3 mm, often asymptomatic, may close on its own), moderate (3–6 mm, usually needs closure), and large (>6 mm, significant symptoms and heart-failure risk).

By clinical significance: silent PDA (no symptoms or murmur), hemodynamically significant PDA, and PDA with heart failure.

By shunt direction: left-to-right (typical) or right-to-left (Eisenmenger syndrome, rare today).

By context: PDA in premature infants (most common), full-term infants, or older children and adults; and isolated PDA versus PDA occurring with other congenital heart defects.

7. Causes of the Disease

PDA is congenital, developing before birth. Contributors include:

Prematurity — the single most important factor; immature ductal tissue responds poorly to oxygen, and higher prostaglandin levels keep the ductus open.
Genetic factors — a modestly increased risk with family history, and higher rates in Down syndrome (trisomy 21).
Maternal factors — first-trimester rubella, poorly controlled diabetes, alcohol use, and certain medications.
Fetal oxygen deprivation — placental problems or fetal hypoxia may impair closure.

Most cases are sporadic, with no cause beyond prematurity.

8. How the Disease Develops

In the fetus, the ductus arteriosus is held open by prostaglandins (chiefly PGE2) and carries much of the cardiac output away from the non-functional lungs. At birth, the first breaths expand the lungs and drop pulmonary resistance, while rising oxygen reduces prostaglandins. The ductal muscle constricts—functional closure within 24–48 hours, then permanent anatomic closure over 1–2 weeks as the vessel fibroses into the ligamentum arteriosum.

In PDA this process fails, far more often in premature infants whose ductal tissue responds poorly to oxygen. Once the ductus stays open, aortic pressure drives a left-to-right shunt, and over weeks to months the left heart chambers dilate, progressing toward heart failure and pulmonary hypertension. PDA is often diagnosed in the neonatal period, but a small, silent defect may not surface until later childhood or, rarely, adulthood.

9. Risk Factors

Prematurity (strongest): risk rises steeply with degree of prematurity—roughly 50–70% of extremely preterm infants (<28 weeks) develop PDA—and with low birth weight (especially <1,000 g).

Perinatal: respiratory distress syndrome, mechanical ventilation, and oxygen deprivation at birth.

Genetic/familial: family history of congenital heart disease, an affected sibling, or syndromes such as Down syndrome.

Maternal: rubella in pregnancy, poorly controlled diabetes, alcohol or drug use, and certain medications.

Other: high-altitude birth and multiple gestation. Most cases occur in premature infants without maternal risk factors.

10. Genetic and Family-History Factors

Most PDA is sporadic rather than inherited, but genetics play a modest role. Siblings of an affected child carry a slightly higher risk, which rises when a previous child had congenital heart disease. PDA occurs more commonly in chromosomal syndromes, particularly Down syndrome. It is considered a complex, polygenic trait—many genes each contributing small effects and interacting with triggers such as prematurity. Fetal echocardiography is recommended when a previous child had congenital heart disease, and genetic counselling suits families with multiple affected children.

11. Who Is Most at Risk?

Premature infants carry by far the highest risk, which rises with prematurity:

Extremely preterm (<28 weeks): ~50–70%
Very preterm (28–32 weeks): ~20–30%
Moderate-to-late preterm (32–37 weeks): ~5–10%

Other higher-risk groups include term infants with Down syndrome or other congenital syndromes, infants with a family history of congenital heart disease, and preterm babies with respiratory distress syndrome or prolonged ventilation. Rarely, undiagnosed silent PDA persists into adulthood. Risk falls sharply with increasing gestational age.

12. Prevalence and Epidemiology

Congenital heart defects occur in about 1% of live births, and PDA accounts for roughly 5–10% of these. Incidence varies dramatically by gestational age: only about 0.02–0.04% in full-term infants, but 10–15% across all preterm infants, rising to 50–70% below 28 weeks. There is a slight female predominance (around 60% of cases). Improved survival of very preterm infants has increased the absolute number of PDA cases. Adult PDA is rare, usually representing small, previously silent defects.

13. Signs and Symptoms

Symptoms vary with PDA size and age.

Premature infants: respiratory distress (rapid breathing, grunting, retractions), rising ventilator or oxygen needs, difficulty weaning off support, poor feeding, a machine-like murmur, bounding pulses, and signs of heart failure.

Full-term infants: a heart murmur is often the first sign; others include poor growth, feeding difficulties, sweating with feeds, fast breathing, and frequent respiratory infections.

Older children and adults with untreated PDA: exercise intolerance, breathlessness on exertion, palpitations, and recurrent respiratory infections.

Small, silent PDA: usually no symptoms and normal growth; often found incidentally on a murmur.

14. Early-Stage Symptoms

Early signs are often subtle. In premature infants, the first clues may be a worsening respiratory status, need for higher ventilator settings, apnea or bradycardia episodes, feeding intolerance, and temperature instability. In full-term infants, early signs include mild tachypnea, occasional feeding pauses, slow weight gain, frequent coughing, and more colds than expected. Across all ages, a heart murmur is often the first objective finding, and recognising these early prevents complications.

15. Advanced-Stage Symptoms

Severe or long-untreated PDA causes marked symptoms.

Heart failure: severe respiratory distress with retractions, poor perfusion, enlarged liver (hepatomegaly), edema, profuse sweating with feeds, and severe failure to thrive.

Pulmonary: recurrent pneumonia, bronchopulmonary dysplasia (in preterm infants), pulmonary hypertension, and respiratory failure.

Cardiovascular: cardiomegaly, bounding pulses, a wide pulse pressure, tachycardia, and a gallop (S3) rhythm.

Eisenmenger syndrome (rare, long-untreated): cyanosis, finger clubbing, coughing up blood, and right-sided heart failure. Advanced symptoms require urgent treatment.

16. Symptoms in Women, Men and Older Adults

Because most PDA is diagnosed in infancy, gender differences in symptoms are minimal—boys and girls present alike—though there is a slight female predominance in incidence. Undiagnosed PDA presenting in adulthood (either sex) may cause exercise intolerance, breathlessness, palpitations, and sometimes atrial fibrillation or heart failure if large. For women with untreated PDA, pregnancy adds cardiovascular stress and raises the risk of arrhythmias and heart failure; ideally the PDA is closed before conception.

17. Emergency Warning Signs

In infants, seek emergency care for severe respiratory distress (gasping, grunting, very fast breathing), central cyanosis (blue lips or tongue), apnea, very slow heart rate, cold or blue extremities, severe lethargy, seizures, feeding refusal, or signs of shock.

In children and adults, seek urgent care for severe chest pain, breathlessness at rest, fainting, a rapid irregular heartbeat, sudden severe weakness, coughing up blood, or sudden swelling with breathing difficulty. When in doubt, seek emergency care—PDA complications can progress rapidly.

18. When to Seek Medical Help

Arrange prompt evaluation for an infant with a new heart murmur, feeding difficulty or poor weight gain, fast breathing, frequent respiratory infections, or sweating with feeds; any cyanosis is an emergency. For children, seek care for exercise intolerance, breathlessness with activity, or poor growth. Adults with unexplained declining exercise capacity, progressive breathlessness, sustained palpitations, or leg swelling should be assessed. Routine screening is also appropriate at well-child visits, preterm follow-up, and sports physicals.

19. Disease Stages, Grades and Severity

PDA is graded rather than formally staged.

By size: small (<3 mm), moderate (3–6 mm), large (>6 mm).

By hemodynamic significance: silent, hemodynamically significant, or PDA with overt heart failure.

By pulmonary effect: no pulmonary hypertension, mild (reversible) pulmonary hypertension, moderate-to-severe (potentially fixed) pulmonary hypertension, and Eisenmenger syndrome.

A practical clinical progression runs from an asymptomatic murmur, through mild feeding difficulty, to failure to thrive and frequent infections, then heart failure, and finally—if untreated for years—Eisenmenger physiology.

20. Disease Progression

Small PDAs often stay stable, may close spontaneously (especially in preterm infants), and can remain silent into adulthood, though a lifelong small risk of endocarditis persists. Moderate-to-large PDAs in infants worsen over weeks to months, producing heart failure, growth failure, and frequent infections; most recover fully if treated in time. Large untreated PDAs in children and adults cause worsening exercise intolerance and progressive pulmonary hypertension, and ultimately atrial fibrillation, heart failure, and Eisenmenger syndrome with reduced lifespan. Modern treatment has transformed this outlook.

21. Possible Complications

Cardiac: heart failure, progressive left heart enlargement, pulmonary hypertension, Eisenmenger syndrome, atrial fibrillation, and infective endocarditis.

Pulmonary: recurrent pneumonia, bronchopulmonary dysplasia and pulmonary hemorrhage (especially in preterm infants), and respiratory failure.

Systemic: failure to thrive, developmental delay, and reduced kidney perfusion.

Treatment-related: bleeding, infection, device embolization, and residual (incomplete) closure. Early treatment prevents most complications.

Coexisting heart defects: ventricular septal defect (VSD), atrial septal defect (ASD), coarctation of the aorta, and aortic stenosis; pulmonary hypertension and heart failure are direct consequences of a significant shunt.

Genetic/congenital syndromes: Down syndrome, other chromosomal abnormalities, and congenital rubella syndrome.

Conditions of prematurity: respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, and intraventricular hemorrhage.

Other: recurrent pneumonia, infective endocarditis, and polycythemia (in Eisenmenger syndrome). Most PDAs, however, are isolated defects.

23. Screening and Early Detection

Who to screen: all premature infants (routine cardiac exam and, in the very preterm, echocardiography with serial follow-up), plus infants with respiratory distress, a family history of congenital heart disease, or maternal rubella exposure.

Methods: physical examination (auscultation for the murmur, checking pulses, monitoring growth); echocardiography (the gold standard, showing ductus size, shunt direction, and heart function); chest X-ray and ECG; and pulse oximetry newborn screening, which can detect a significant PDA.

24. How the Disease Is Diagnosed

Diagnosis begins with the history and a physical examination. The classic finding is a continuous, “machine-like” murmur at the left upper sternal border, often with bounding pulses and a wide pulse pressure; a significant shunt may add tachycardia and an enlarged liver.

Echocardiography is the gold standard. Transthoracic echo with color and spectral Doppler confirms the diagnosis, measures ductus diameter, demonstrates shunt direction and magnitude, assesses left-sided chamber enlargement, estimates pulmonary artery pressure, and rules out other defects. Supporting studies include a chest X-ray (cardiomegaly, increased pulmonary markings) and an ECG (often normal, or showing chamber enlargement). Cardiac catheterization is now used mainly for treatment or to assess pulmonary hypertension.

25. Physical Examination and Medical History

History focuses on the perinatal course—gestational age, birth weight, respiratory distress, ventilation and oxygen needs, and complications of prematurity—together with symptoms and family or maternal history. Examination assesses growth, general appearance, respiratory effort, and perfusion. The cardiovascular exam typically reveals the continuous murmur at the left upper sternal border, bounding pulses with a wide pulse pressure, and a possible gallop if heart failure is present. Crackles, hepatomegaly, or edema suggest heart failure; cyanosis suggests Eisenmenger physiology. Echocardiography then confirms the diagnosis.

26. Diagnostic Tests and Imaging

Echocardiography is the primary test: transthoracic echo provides imaging of the ductus, color Doppler of the shunt, spectral Doppler for flow and pressure estimates, and assessment of chamber size and function. Transesophageal echo helps guide catheter closure. Chest X-ray may show cardiomegaly and increased pulmonary markings. ECG is often normal with small PDAs but may show left ventricular hypertrophy or, with pulmonary hypertension, right ventricular hypertrophy. Cardiac CT/MRI is reserved for complex anatomy, and cardiac catheterization is chiefly therapeutic today. Supportive labs include BNP/NT-proBNP. Echocardiography remains definitive.

27. Blood Tests, Biomarkers and Genetic Testing

PDA is diagnosed by imaging, not blood tests, but labs provide support. BNP and NT-proBNP rise with heart failure and can track treatment response. A complete blood count may show polycythemia in Eisenmenger syndrome or raised white cells if endocarditis is suspected. Kidney and liver function, electrolytes, and coagulation studies matter before procedures and during diuretic therapy. Genetic testing is not routine, since most PDA is isolated; it is reserved for infants with features suggesting a syndrome. Newborn pulse-oximetry screening can detect a significant PDA before discharge.

28. Understanding Test Results

Echocardiography provides the key numbers. Ductus size guides treatment: <3 mm (small, may not need closure), 3–6 mm (moderate, usually closed), >6 mm (large, requires closure). A left-to-right shunt is typical; a right-to-left or bidirectional shunt signals pulmonary hypertension or Eisenmenger physiology. Left atrial/ventricular enlargement reflects volume overload. On chest X-ray, cardiomegaly and increased lung markings suggest a significant shunt. Pulse oximetry below 95% raises concern for Eisenmenger syndrome, and elevated BNP/NT-proBNP indicates heart failure. Review all results with your pediatric cardiologist.

29. Differential Diagnosis

Several conditions can mimic PDA and are distinguished by echocardiography.

Other causes of a continuous murmur: aortopulmonary window, coronary artery fistula, and pulmonary arteriovenous malformation.

Other infant murmurs (not continuous): VSD (holosystolic), ASD (fixed split S2), and aortic or pulmonary stenosis (systolic).

Other causes of neonatal respiratory distress: respiratory distress syndrome, sepsis, pneumonia, and transient tachypnea.

Other causes of infant heart failure: critical aortic stenosis, hypoplastic left heart syndrome, and coarctation. Echocardiography reliably separates these.

30. Specialist and Multidisciplinary Evaluation

PDA care is team-based. The pediatric cardiologist leads diagnosis, medical management, catheter closure, and follow-up. A neonatologist manages preterm infants, including respiratory support and NSAID therapy. The pediatric interventional cardiologist performs device closure, and the pediatric cardiac surgeon handles surgical ligation and cases unsuitable for catheter closure. Supporting members include cardiac nurses, respiratory therapists, dietitians, social workers, and genetic counsellors. Explore our network of doctors and hospitals.

31. Treatment Goals

The immediate aims are to close the PDA, eliminate the abnormal shunt, relieve symptoms, and prevent complications such as heart failure, pulmonary hypertension, and endocarditis. The long-term goals are normal growth and development, normal exercise tolerance, prevention of irreversible pulmonary hypertension, and a normal lifespan. The approach is individualized—ranging from NSAIDs in preterm infants, to catheter closure for most others, to surgery when catheter closure is unsuitable, to observation for a tiny, silent PDA. Success means complete closure, symptom resolution, catch-up growth, and preserved cardiac function.

32. When Is Treatment Required?

Treatment is clearly indicated for a symptomatic or hemodynamically significant PDA—one causing heart failure, respiratory compromise, poor feeding and growth, or recurrent infections, or producing left heart enlargement. Large PDAs (>3 mm, and almost always >6 mm) and any symptomatic PDA in a term infant require closure. Adults with PDA are generally advised to have it closed—even when asymptomatic—to prevent endocarditis and late complications. Treatment may be deferred for a tiny, silent PDA (<2–3 mm) with no chamber enlargement, particularly in preterm infants where spontaneous closure is likely. Closure is contraindicated in Eisenmenger syndrome.

33. Active Monitoring and Watchful Waiting

Observation suits carefully selected patients: preterm infants with a small (<2–3 mm), minimally symptomatic PDA and no heart failure, and term infants with a very small, silent PDA and excellent growth. Monitoring includes serial echocardiograms, frequent examinations, and attention to growth, feeding, and respiratory status. Observation should stop—and closure be arranged—if symptoms worsen, growth deteriorates, heart failure appears, or the PDA or left heart chambers enlarge. Most PDAs ultimately need treatment; watchful waiting applies only to highly selected cases.

34. Medications

NSAIDs are the mainstay for preterm infants, inhibiting prostaglandin production to promote ductal closure:

Indomethacin — first-line; IV or oral over about three doses, closing roughly 70–80% of PDAs. Requires monitoring for reduced kidney function, platelet dysfunction, and intestinal complications.
Ibuprofen — similar efficacy (~60–70%) with fewer kidney effects.
Acetaminophen (paracetamol) — an emerging alternative with a gentler side-effect profile; not yet first-line.

Supportive medications treat heart-failure symptoms rather than closing the PDA: diuretics such as furosemide relieve congestion, inotropes support failing hearts, and antibiotics treat or prevent endocarditis. NSAIDs work only in premature infants; older patients need device or surgical closure.

35. Minimally Invasive Treatments

Transcatheter device closure is the primary treatment for most PDAs beyond the preterm period. Through a small femoral-vein puncture, a catheter is guided to the ductus under imaging, and an occlusion device is deployed across the PDA and confirmed before the catheter is removed. Devices include detachable coils (small-to-moderate PDAs) and Amplatzer-type occluders (a range of sizes). Benefits include no chest incision, a short (usually overnight) stay, recovery within days, and closure success above 95%. Limitations include very small or very large PDAs, low infant weight, and unfavorable anatomy. Explore minimally invasive cardiac procedures.

36. Catheter-Based and Endovascular Treatments

Ideal candidates are term infants (typically >6 months and >6 kg), children, and adults with suitable anatomy—usually a moderate PDA and no prohibitive pulmonary hypertension. Under general anesthesia or sedation, access is via the femoral vein; a guidewire crosses the PDA, a delivery sheath is advanced, and the occlusion device is positioned, confirmed by imaging, then released. The child is observed overnight with a repeat echocardiogram before discharge. Modern devices achieve immediate closure in over 90% and complete closure above 95% at follow-up, with major complications under 5%. This is the standard of care for most suitable PDAs. See endovascular stenting.

37. Surgical Treatment Options

Surgical closure is used when catheter closure is unsuitable: very large PDAs, unfavorable anatomy, failed device closure, very small infants, or when other cardiac defects need simultaneous repair.

The traditional approach is a left thoracotomy—an incision between the ribs on the left chest—through which the ductus is dissected free and closed by ligation (tying it off) or clipping. Minimally invasive alternatives include video-assisted thoracoscopic surgery (VATS) and robot-assisted surgery; a median sternotomy is used when other heart surgery is done at the same time.

Benefits: definitive closure with a very high success rate, suitability for any PDA size or shape, and the ability to combine with other repairs. Risks: bleeding, infection, injury to nearby structures (notably the recurrent laryngeal nerve, causing hoarseness), and anesthesia risks. Recovery involves a 2–5 day stay and return to normal in about 4–6 weeks. Surgery remains an excellent option when catheter closure is not appropriate. See congenital heart procedures.

38. Advanced and Emerging Treatments

Hybrid procedures combine surgical and catheter techniques—for example, perventricular device placement through a small needle puncture of the heart—to enable closure in very small infants (under about 2 kg). Advanced catheter techniques include newer devices for challenging anatomy, multiple devices or covered stents for very large PDAs, and 3D-printed models for planning. Pulmonary hypertension from long-standing PDA is managed with vasodilators such as sildenafil or bosentan; in established Eisenmenger syndrome, closure is avoided, treatment focuses on pulmonary hypertension therapy, and transplantation is considered in severe cases.

39. Treatment Options Compared

Treatment	Best For	Advantages	Disadvantages	Recovery
Medical therapy (NSAIDs)	Preterm infants, small PDA	Non-invasive, effective in preterm	Side effects (kidney, intestines); ineffective in term infants	No procedure; monitor for side effects
Catheter device closure	Term infants >6 months, children, adults	Minimally invasive, high success, short stay	Not for very small/large PDA; possible residual shunt	~1 day hospital; normal activity in 3–5 days
Surgical ligation	Large PDA, unfavorable anatomy, failed catheter closure, tiny infants	Definitive; suits all sizes; can combine with other surgery	More invasive; chest incision; longer recovery	2–5 days hospital; full recovery 4–6 weeks
Hybrid procedures	Very small infants (<2 kg), complex cases	Enables closure in tiny infants	Limited availability; specialized expertise	Varies by approach

Choice depends on gestational age and size, PDA size and anatomy, symptoms, associated conditions, and center expertise. Most suitable patients undergo catheter closure.

40. How Doctors Choose the Right Treatment

Selection is individualized by patient factors (gestational age, size, age, symptoms, associated conditions) and PDA factors (size, shape, hemodynamic significance, shunt direction). In practice: preterm infants typically receive an NSAID trial first, with surgery if that fails or the PDA is large; term infants and children usually undergo catheter closure when anatomy allows; and adults generally have catheter closure, with medical therapy alone if Eisenmenger syndrome has developed. A Heart Team—cardiologist, interventional cardiologist, and surgeon—reaches a consensus recommendation through shared decision-making with the family.

41. Benefits and Risks of Treatment

Medical therapy (NSAIDs): non-invasive and effective in 70–80% of preterm infants, but risks kidney dysfunction, rare intestinal perforation, and bleeding, and is ineffective in term infants.

Catheter closure: minimally invasive with >95% closure, a short stay, and fast recovery; risks include puncture-site bleeding, vessel injury, rare device embolization, small residual shunt, and transient arrhythmias.

Surgical closure: definitive and suitable for all PDAs, and combinable with other repairs; risks include bleeding, infection, injury to nearby structures, a scar, and a longer recovery. For appropriately selected patients, the benefits of closure substantially outweigh the risks.

42. What Happens If the Disease Is Left Untreated?

Small, silent PDAs may stay stable or close spontaneously, but carry a lifelong small risk of endocarditis. Moderate-to-large PDAs in infants progress over months to heart failure, failure to thrive, recurrent infections, and rising pulmonary pressures. In children and adults, untreated large PDAs lead to worsening exercise intolerance, atrial fibrillation, heart failure, fixed pulmonary hypertension, and ultimately Eisenmenger syndrome with reduced life expectancy. Historically, large untreated PDAs caused high infant mortality; modern treatment has reversed this, with timely closure preventing most complications.

43. Treatment Success and Expected Outcomes

Treatment is highly successful. Medical therapy closes 70–80% of PDAs with indomethacin and 60–70% with ibuprofen, usually within days; failures can be re-treated or referred for closure. Catheter closure achieves immediate closure in over 90% and complete closure above 95%, with small residual shunts (about 5%) usually resolving on their own. Surgical ligation closes over 98%, with recurrence under 2%. After closure, respiratory symptoms and feeding improve within days, most infants achieve catch-up growth, the heart returns to normal size over months, and arrhythmias often resolve.

44. Prognosis and Long-Term Outlook

With modern treatment the prognosis is excellent. Most patients achieve a near-normal lifespan, normal growth and development, normal cardiac function after closure, and full quality of life.

Outlook depends chiefly on timing and complications before closure. Early closure, before pulmonary hypertension or ventricular dysfunction sets in, gives the best results; late closure may leave residual pulmonary hypertension or heart enlargement. Small PDAs have an excellent prognosis even if never treated. Established Eisenmenger syndrome carries a poor prognosis and precludes closure. Long-term follow-up includes periodic echocardiograms and endocarditis prophylaxis for about 6 months after closure. After successful closure, patients typically face no restrictions on sports, pregnancy, employment, or insurance.

45. Recovery and Rehabilitation

After medical therapy, there is no procedural recovery, but infants are monitored for side effects while feeds are advanced. After catheter closure, the stay is usually one night; rough play is avoided for 1–2 weeks, a confirmatory echocardiogram is done before discharge, and endocarditis prophylaxis continues for about 6 months, with normal activities resuming within 3–5 days. After surgical closure, the stay is typically 2–5 days; incision care, breathing exercises, and activity limits apply for 4–6 weeks. Children return to school promptly after catheter closure or within a few weeks after surgery.

46. Follow-Up Tests and Long-Term Monitoring

After catheter closure, the first follow-up is at 2–4 weeks with echocardiography to confirm closure and check for residual shunt, then periodic reviews (typically 6–12 months, then as needed). After surgery, follow-up includes an incision check and echocardiogram at 2–4 weeks. All PDA patients benefit from lifelong cardiac follow-up: regular examinations, periodic echocardiography, endocarditis prophylaxis and good dental hygiene for about 6 months after closure, and monitoring of growth and exercise tolerance. Patients should report new symptoms such as chest pain or palpitations, maintain dental health, and avoid smoking.

47. Managing Recurrence or Disease Progression

After NSAIDs, the PDA can re-open—more likely with extreme prematurity—and may be re-treated with a second course or referred for closure. After catheter closure, tiny residual leaks are common and usually seal spontaneously; a significant residual PDA may need a second device or surgery. After surgical ligation, recurrence is rare (<2%) and is managed with repeat closure. If pulmonary hypertension has become fixed after late closure, it is managed with targeted medications; residual ventricular dysfunction is treated with standard heart-failure therapy. Most recurrences are readily treatable.

48. Living with the Disease

After successful closure, most patients live entirely normal lives with no restrictions on school, sports, play, or work, and life expectancy is normal. Ongoing care means regular cardiology follow-up, periodic echocardiograms, good dental hygiene with endocarditis prophylaxis for 6 months after closure, and prompt attention to fever. Most children develop normally, surgical scars fade, and procedural anxiety resolves with time. Pregnancy, employment, and insurance are generally unaffected, and regular exercise is encouraged.

49. Diet and Nutrition Guidelines

Infants with PDA often have increased caloric needs yet tire during feeds. Helpful strategies include frequent, smaller feeds, high-calorie fortified formula or breast milk, and—when oral intake is inadequate—feeding-tube support, with close weight monitoring. After closure, feeds advance normally and most infants achieve catch-up growth.

Children and adults with treated PDA need no special diet—just a heart-healthy pattern (Mediterranean, DASH, or plant-based): plenty of fruits, vegetables, and whole grains; lean proteins; healthy fats; and limited processed foods, saturated and trans fats, added sugars, and sodium.

50. Exercise and Physical-Activity Guidelines

After catheter closure, normal activities resume within 3–5 days, with rough play avoided for 1–2 weeks; there are no long-term restrictions once recovered. After surgery, initial rest is followed by a gradual increase in activity, with no lifting for 4–6 weeks. Normal developmental activities are encouraged for infants after closure, and school-age children participate fully in sports with cardiologist clearance for competitive athletics. Sensible precautions include stopping for chest pain, breathlessness, or dizziness.

51. Medications, Activities and Habits to Avoid

Medications: prostaglandin (PGE1) keeps the ductus open and is avoided in PDA; NSAIDs after closure should be used only when necessary; and blood thinners require caution. For about 6 months after closure, dental procedures may need antibiotic prophylaxis, and IV drug use is absolutely contraindicated because of endocarditis risk.

Activities: before closure, avoid strenuous exercise if symptomatic, and high-altitude activities or scuba diving with significant pulmonary hypertension. After catheter closure, avoid rough play for 1–2 weeks; after surgery, avoid heavy lifting and contact sports for 4–6 weeks. Long-term, no restrictions apply once healed.

Habits: avoid smoking and secondhand smoke, limit alcohol, and maintain good diet and dental hygiene.

52. Preventing the Disease or Reducing Its Risks

PDA usually cannot be prevented, but risks can be reduced. Before birth, good prenatal care matters: controlling maternal diabetes, ensuring rubella immunity through vaccination, avoiding alcohol, tobacco, and harmful medications, and eating well. Because prematurity is the biggest risk factor, preventing preterm birth reduces PDA risk. After birth, careful monitoring of premature infants allows prompt diagnosis, and newborn pulse-oximetry screening helps detect significant defects. Once diagnosed, early, complete closure with appropriate follow-up prevents most complications.

53. Pregnancy and the Disease

Ideally, a known PDA is closed before pregnancy to prevent heart failure and arrhythmias during its added cardiovascular demands. After successful closure, pregnancy is usually uncomplicated, with standard obstetric care plus cardiac follow-up and typically safe vaginal delivery. A significant PDA discovered during pregnancy is assessed by echocardiography and managed by a multidisciplinary team; closure during pregnancy is rarely needed, though untreated it raises the risk of arrhythmias and heart failure. Some cardiac medications (such as ACE inhibitors) are unsafe in pregnancy and require adjustment. Pre-conception counselling is recommended for women with known PDA.

54. Disease in Children and Young Adults

Infants are the most common age group, especially preterm babies, presenting with murmur, feeding difficulty, poor growth, respiratory symptoms, or heart failure; treatment timing depends on symptoms, size, and gestational age. Toddlers and preschoolers with a previously undiagnosed PDA may be asymptomatic or show exercise intolerance, frequent infections, or poor growth, and usually undergo catheter closure. In school-age children, adolescents, and young adults, a new diagnosis is rare—often a murmur found on a sports physical—and catheter closure is preferred, with an excellent prognosis. Across all ages, athletic participation is usually allowed after closure.

55. Disease in Older Adults

PDA diagnosed in adulthood is rare, usually a small defect silent since childhood. Adults may present with increasing exercise intolerance and breathlessness, or the PDA may be found incidentally; by this stage, atrial enlargement, atrial fibrillation, or pulmonary hypertension may have developed. Diagnosis relies on echocardiography, with catheterization sometimes needed to assess pulmonary hypertension. Catheter closure is preferred when anatomy is suitable; surgery is an alternative, and medical therapy alone is used if Eisenmenger syndrome has developed. Outcomes are excellent when closure precedes fixed complications, and symptoms typically improve significantly.

56. Emotional Health and Patient Support

A PDA diagnosis can trigger shock, anxiety, guilt, and fear. Parents of premature infants face particular stress from the NICU experience and financial strain, with a higher risk of postpartum depression. Children and adolescents may feel anxious about procedures or self-conscious about scars. Support helps enormously: open, age-appropriate communication; supporting siblings; and professional help from social workers, child life specialists, and psychologists, plus peer support groups for congenital-heart families. Most children adjust well and develop normally after successful treatment.

57. Preparing for Your Specialist Appointment

Before the visit, gather the pregnancy and birth history (especially gestational age, birth weight, and neonatal course), a record of symptoms, growth measurements, previous test results, a current medication list, and relevant family history. Prepare a list of questions about the diagnosis, PDA size, treatment options, urgency, outcomes, risks, and follow-up. During the appointment, be specific, ask when unclear, and take notes. For infants, bring feeding supplies and comfort items, since a calm baby helps echocardiography.

58. Questions to Ask Your Doctor

What exactly is patent ductus arteriosus, and how is it affecting my child’s heart?
How large is the PDA—small, moderate, or large—and is it causing symptoms?
Are there any other heart problems associated with it?
What treatment options are available, and which do you recommend and why?
How urgent is treatment—can we wait, or does it need to be done soon?
What are the risks, benefits, and success rates of the recommended treatment?
What happens if we choose not to treat the PDA?
What does the procedure involve, how long is the hospital stay, and what is recovery like?
What follow-up care and activity restrictions should we expect, and will antibiotics be needed before dental work?
Will my child have a normal life expectancy and fertility, and what warning signs require emergency care?

59. Cost of Diagnosis and Treatment

Service	United States	India	Turkey	Thailand	Singapore
Cardiology consultation	$200–500	$50–150	$80–200	$100–250	$200–400
Echocardiography	$500–2,000	$100–300	$150–400	$200–500	$300–800
Chest X-ray / ECG	$100–800	$30–150	$50–200	$80–250	$100–400
Medical therapy (NSAID course)	$500–2,000	$100–400	$150–500	$200–600	$300–800
Catheter closure (device + procedure)	$15,000–40,000	$3,000–8,000	$5,000–12,000	$6,000–15,000	$10,000–20,000
PDA ligation surgery	$20,000–50,000	$4,000–12,000	$6,000–15,000	$8,000–18,000	$12,000–25,000
Hospital stay (per day)	$2,000–8,000	$200–600	$300–800	$400–1,000	$600–1,500

All prices are approximate and vary by hospital, physician, and case complexity. Medical-tourism destinations such as India, Turkey, and Thailand often cost 50–90% less than the US or UK. The device is a significant part of catheter-closure cost; for preterm infants, PDA care is usually part of larger NICU expenses. Additional costs include travel, accommodation, and follow-up. See our destinations guide.

60. Factors Affecting Treatment Cost

Location and hospital: country and region, private versus public setting, reputation, and accreditation (JCI often signals higher cost but assured quality).

Provider: specialist experience and reputation, procedure volume, and team size.

Treatment approach: catheter closure carries significant device costs but a shorter stay; surgery adds operating-room and longer-stay costs; medical therapy is cheaper initially but may fail; emergencies and complications sharply increase costs.

Patient factors: age, size, gestational age (preterm infants incur higher NICU costs), comorbidities, and length of stay.

Additional: pre-treatment testing, medications, follow-up, travel, lost wages, and childcare, plus wide variation in insurance coverage.

61. Choosing the Right Specialist

For a pediatric cardiologist, look for board certification, specific training in congenital heart disease, substantial PDA experience, a strong hospital affiliation, and clear communication. For a pediatric interventional cardiologist, prioritize high procedural volume, excellent closure rates (>95%), and access to multiple device options. For a pediatric cardiac surgeon, seek pediatric specialization, high surgical volume, and a strong supporting team. For preterm infants, a neonatologist with a Level III–IV NICU and close cardiology collaboration is key. Also weigh location, insurance network, and openness to second opinions. Browse our doctors directory.

62. Choosing the Right Hospital or Treatment Centre

Hospital quality strongly affects PDA outcomes. Look for accreditation—Joint Commission International (JCI) is the international gold standard—plus children’s-hospital designation and a Level III–IV NICU for preterm infants. Volume and experience matter: centers performing many PDA closures, with 24/7 cardiac coverage and full-service pediatric cardiac care (interventional cardiology, cardiac surgery, and a dedicated cardiac ICU), tend to have better results. Assess outcomes (target >95% for catheter closure, >98% for surgery), complication and readmission rates, and transparency. For international patients, check language access, dedicated international-patient services, cost transparency, and clear post-discharge arrangements. Explore accredited hospitals.

63. Getting a Second Medical Opinion

A second opinion is worthwhile—particularly when surgery is recommended, when different doctors suggest different approaches, when the case is complex, or simply when you want confirmation before proceeding. Good doctors welcome it, and most insurers cover it for cardiac procedures. To make it productive, bring all records, be open about the first opinion, and ask focused questions. A second opinion can confirm the plan, offer an alternative perspective, reveal additional options, or clarify your understanding. Virtual second opinions are increasingly available, including from international centers. Request one via our contact page.

64. Treatment Abroad and Medical-Travel Considerations

Medical tourism for PDA is increasingly common. Popular destinations include India (excellent pediatric cardiac centers, ~60–80% savings, English-speaking), Turkey and Thailand (modern facilities, ~60–70% savings), and Singapore (world-class, higher cost). Advantages include major cost savings even after travel, JCI-accredited facilities, high-volume teams, and shorter waits. Weigh the challenges too: communication barriers, continuity of care after returning home, handling complications, and insurance coverage. When choosing a center, insist on JCI accreditation, verified physician credentials and outcomes, a dedicated international-patient department, and a clear post-discharge plan. Transfer records ahead, and arrange local follow-up before departure. Many families travel successfully with excellent outcomes.

65. Frequently Asked Questions

Q: Will my child outgrow PDA without treatment? A: Small PDAs (<2–3 mm), especially in premature infants, may close on their own, but moderate and large PDAs rarely do and usually need treatment. Delaying closure of a significant PDA risks heart failure, poor growth, and pulmonary hypertension.

Q: Will my child need open-heart surgery? A: Usually not. Most PDAs are closed by catheter—a minimally invasive procedure through a leg vessel that avoids opening the chest. Catheter closure typically takes 1–3 hours with an overnight stay. Surgery is reserved for very large PDAs, unusual anatomy, or when catheter closure isn’t suitable, and involves a 2–5 day stay.

Q: Can PDA come back after closure? A: Recurrence is uncommon. Over 95% remain closed after catheter closure; small initial leaks usually seal as the device endothelializes. Surgical ligation recurs in under 2%, and any recurrence is usually treated with a second procedure.

Q: Will my child have activity restrictions afterward? A: After recovery, most children have no long-term restrictions and can play all sports. Rough play is limited for 1–2 weeks after catheter closure, and activity for 4–6 weeks after surgery.

Q: Does PDA closure affect lifespan? A: With timely closure, lifespan and quality of life are typically normal. Untreated large PDAs can shorten lifespan through heart failure and pulmonary hypertension, so the goal is closure before permanent complications develop.

Q: Will my child need antibiotics before dental work? A: Guidelines recommend prophylaxis for dental procedures for about 6 months after closure. After that, if closure is complete with no residual leak, it is generally no longer needed—confirm with your cardiologist.

Q: Can PDA be detected during pregnancy? A: The ductus is normally open in the fetus, so PDA itself is diagnosed after birth when it fails to close. Fetal echocardiography can, however, detect associated congenital heart defects.

66. Patient Stories and Treatment Experiences

The following are representative composites and do not identify specific individuals.

Emma, born at 26 weeks — Australia. Extremely premature at 800 grams, Emma developed worsening respiratory distress at two weeks, and echocardiography showed a large PDA. When indomethacin failed and she was still under 1 kg, surgical ligation was chosen. “We were terrified—our tiny baby needing heart surgery. But her breathing improved dramatically within days.” She later came off the ventilator and grew well.

Ravi, 8 — India. Always a little slower at sports, Ravi was found to have a murmur at a school physical, and echocardiography revealed a previously undiagnosed moderate PDA. He had catheter closure as a day procedure and went home the next day. “A year later, he’s running faster than ever.” Ravi needs no medications and has no restrictions.

Sophie, 28 — United Kingdom. Long attributing exertional breathlessness to being unfit, Sophie was diagnosed at 27 with a moderate PDA after a routine physical detected a murmur, and underwent catheter closure. “Recovery was quick—I was back to work in a week, and now I can exercise without getting winded.”

These stories illustrate the range of PDA presentations and the excellent outcomes achievable with appropriate treatment.

67. Latest Research and Clinical Trials

Research continues to refine PDA care. In premature infants, studies focus on the optimal timing of treatment, which babies truly benefit, acetaminophen as an alternative to NSAIDs, and long-term neurodevelopmental outcomes. Device technology is advancing toward smaller and bioresorbable devices and improved delivery systems, and imaging advances include 3D and fetal echocardiography. Long-term studies follow adults who had childhood closure, and other work addresses predicting reversibility of pulmonary hypertension and the genetics of PDA. Families interested in trials should ask their pediatric cardiology center about current studies.

Atrial Septal Defect — hole between the upper chambers; may coexist with PDA
Ventricular Septal Defect — hole between the lower chambers; may occur with PDA
Aortopulmonary Window — a similar, more serious aorta-to-pulmonary-artery connection
Tetralogy of Fallot — complex defect sometimes including a PDA
Heart Failure — pump failure from chronic volume overload
Infective Endocarditis — infection risk increased by PDA
Congenital Heart Disease — the broader category of congenital defects

Congenital Heart Procedures — catheter and surgical PDA closure
Minimally Invasive Cardiac LIS — catheter-based closure
Hybrid Cardiac Procedures — combined approaches for complex cases
Endovascular Stenting — related catheter technology
Video-Assisted Thoracic Surgery — minimally invasive surgical approach

Browse all procedures.

70. Medical Glossary

Cardiac catheterization — a procedure using a thin tube guided into the heart for diagnosis or treatment.

Cyanosis — bluish skin, lips, or nail beds caused by low blood oxygen.

Ductus arteriosus — the fetal vessel connecting the pulmonary artery to the aorta, bypassing the lungs before birth.

Echocardiography — ultrasound imaging of the heart’s structure, function, and blood flow.

Eisenmenger syndrome — reversal of the shunt from severe pulmonary hypertension, causing low blood oxygen.

Endocarditis — infection of the heart lining or valves; risk is raised by structural defects like PDA.

Hemodynamically significant PDA — a PDA large enough to affect heart function and warrant closure.

Indomethacin — an NSAID used to close PDA in preterm infants by blocking prostaglandins.

Left-to-right shunt — abnormal blood flow from the higher-pressure left side to the right side, as in PDA.

Ligamentum arteriosum — the fibrous remnant of a normally closed ductus arteriosus.

Pulmonary hypertension — elevated pressure in the pulmonary arteries; can complicate long-standing PDA.

71. Medical Review, Editorial Policy and Last Updated Date

Last updated: 11 July 2026

Medical review policy: This content is reviewed and updated regularly by pediatric cardiac specialists to ensure accuracy and alignment with current practice. It reflects consensus guidelines from major cardiology bodies (AHA, ACC, ESC) and standard pediatric cardiology references.

Editorial policy: Content is written for patient and family education, presented clearly without oversimplification. Treatment options reflect evidence-based medicine; no specific commercial products, devices, or hospitals are endorsed; and cost estimates are approximate.

Disclaimer: This information is educational only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified health provider with any questions about a medical condition, and never disregard or delay seeking it because of something you have read here. For a possible medical emergency, contact emergency services immediately.

72. Clinical Guidelines and Medical References

This content is consistent with current clinical practice guidance from major bodies, including:

American Heart Association / American College of Cardiology (AHA/ACC) guidelines on congenital heart disease
American Academy of Pediatrics guidance on patent ductus arteriosus in preterm infants
European Society of Cardiology (ESC) guidelines for adult congenital heart disease and for cardiovascular disease in pregnancy

Standard references include Moss and Adams’ Heart Disease in Infants, Children, and Adolescents and other established pediatric cardiology textbooks. Reputable patient resources include the American Heart Association and the Adult Congenital Heart Association.

73. Book an Appointment or Request a Second Opinion

Take control of your child’s heart health today. If your child has been diagnosed with patent ductus arteriosus, or you have concerns about possible congenital heart disease, don’t wait—early intervention prevents complications and ensures the best outcomes.

We can help you connect with top pediatric cardiac specialists and accredited children’s hospitals worldwide, explore treatment options, get a second opinion, and access high-quality, affordable care abroad with help on records transfer and travel.

Get started:

Book online: /contact/
Contact us: /contact/
Email: info@bestheartsurgery.com

With modern pediatric cardiac care, most children live completely normal, healthy lives after PDA closure. Take the first step today.

Disclaimer: This service provides information and connection to healthcare providers. We do not provide medical advice or diagnosis. Always consult qualified healthcare professionals, especially pediatric cardiologists, for decisions regarding a child’s health.

Patent Ductus Arteriosus